About: Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 September 1997

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) bài báo khoa học (vi) наукова стаття, опублікована у вересні 1997 (uk) im September 1997 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en setiembre de 1997 (ast) scientific article published on 01 September 1997 (en)
publication date	wds:Q73744392-B11EB368-E973-4F81-8F3C-E8874DDFBE96
publication date	1997-09-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q73744392-A38656AC-696C-483D-B391-3B58037719F4
language of work or name	English
author name string	wds:Q73744392-169A8E3A-470F-4D66-8152-2DDDC0E1F5F8 wds:Q73744392-226D86D7-5BDE-4429-8BAD-0317E1CE0358 wds:Q73744392-252F561B-5A01-4516-A819-21D198329D1A wds:Q73744392-4815F46B-CEDA-4F08-A22F-321DD590C8DA wds:Q73744392-597A9920-A5CB-4886-9299-4882CEFDFD76 wds:Q73744392-6D097F8B-A5B7-4D0C-9863-E28C9FD9EBCF wds:Q73744392-6F818633-E488-40C9-AF4A-CF3D0E15901E wds:Q73744392-828B67D7-D9F2-4566-A0B9-7C7A4747BF2A wds:Q73744392-ECF10AA5-91E3-4218-913A-4975A0576701 wds:Q73744392-FB61900E-6646-4322-97C0-57A20FA68FD9 wds:Q73744392-FE9EB65E-80E4-4B62-943B-02CC20A5DD29
author name string	L K Jennings M M White D R Phillips R M Scarborough S J Shattil C Longhurst J A Jakubowski W Teng A Arfsten A Randolph L Nannizzi-Alaimo
rdfs:label	Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate (en) Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate (nl)
skos:prefLabel	Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate (en) Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate (nl)
name	Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate (en) Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate (nl)
title	wds:Q73744392-78A00AB2-A7EC-4E2E-9389-0A3FF3892241
title	Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate (en)
page(s)	wds:Q73744392-4061188C-E492-4FA5-BF77-454ACC42A857
page(s)	1488-1494
instance of	wds:Q73744392-456A73D5-BAC6-449F-A394-C821532D4981
instance of	scholarly article
main subject	wds:Q73744392-5959F4AC-27B4-4B68-B08B-4DE0E77DA685
main subject	platelet aggregation
PubMed ID	wds:Q73744392-98C6798F-25A8-4C87-95A8-27214F1ACC92
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9315536
PubMed ID	9315536
published in	wds:Q73744392-DB7E2F28-193E-45A1-A7FC-E9F369A69DA8
published in	Circulation
issue	wds:Q73744392-DE4DD949-50D8-4A98-9E4F-59D38E6B4E11
volume	wds:Q73744392-DCC9C991-A575-4E0F-8CA9-4762A30D05F5
issue	5
volume	96
DOI	wds:Q73744392-69A48181-094A-4485-A232-0E1FACABA8E8
DOI	http://dx.doi.org/10.1161/01.CIR.96.5.1488
DOI	10.1161/01.CIR.96.5.1488
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73744392
is cites work of	Platelet function assays Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization Comparative Pharmacology of GP IIb/IIIa Antagonists Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention Platelet PlA2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics A CD9, alphaIIbbeta3, integrin-associated protein, and GPIb/V/IX complex on the surface of human platelets is influenced by alphaIIbbeta3 conformational states Expression of ligand-induced binding sites on glycoprotein IIb/IIIa complexes and the effect of various inhibitors Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial Integrin targeted therapeutics Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. Hemocompatibility of silicon-based substrates for biomedical implant applications A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban Effects of anticoagulant on pH, ionized calcium concentration, and agonist-induced platelet aggregation in canine platelet-rich plasma Integrilin prevents prolonged bleeding times after cardiopulmonary bypass. Development of eptifibatide Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Integrin αIIbβ3: from discovery to efficacious therapeutic target In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIB-IIIa antagonists Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist Eptifibatide: The evidence for its role in the management of acute coronary syndromes Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials Platelet aggregation inhibitors for use in peripheral vascular interventions: what can we learn from the experience in the coronary arteries? Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function Platelet glycoprotein IIb/IIIa receptor antagonists and coronary artery disease Anti-platelet therapy: glycoprotein IIb-IIIa antagonists Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 193 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software